Laval University To Add Women's Hockey Joining U Sports In 2026
"The topic came up in the news a few times a year, and now it's done: university hockey is returning to the Rouge et Or family," said Julie Dionne, Director of the Sports Activities Department at Laval University in a translated school news release.
"With the growing popularity of women's hockey and the absence of a French-language university team outside of Montreal, the arrival of the Rouge et Or comes at a perfect time. There is a tremendous desire to grow this sport and make it a destination of choice for dozens of young women who want to compete at a high level while pursuing university studies. Establishing a new team of this magnitude obviously requires a lot of resources—financial, human, and material—but we firmly believe the investment is worth it. The support of the Quebec City business community and hockey fans will be vital to the success of this new team. "
It will mark a new era for women's hockey in Quebec City where the community recently made a bid for a PWHL team drawing more than 18,000 fans to a PWHL Takeover Tour game this winter.
Laval University will join the University of Montreal, McGill University, Concordia University, and Bishop's University in the province of Quebec as U Sports women's hockey teams. Laval University will now begin the process of recruiting staff and players.
"Building a team from scratch is a colossal undertaking," said Jean-Noël Corriveau, Assistant Director and Head of the Rouge et Or program in the school's release. "Our goal is to be competitive quickly, and we hope to hire a coach in the coming weeks. That's why it was important to open the application process as soon as the announcement was made. Recruitment will be very important, and the successful candidate will have to put in a lot of effort from the moment they take the job."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vf
Yahoo
2 hours ago
- Yahoo
GREY GOOSE® VODKA CELEBRATES TENNIS SEASON WITH FRANCES TIAFOE AND THE "LAST SERVE BAR" AT GRAND CENTRAL TERMINAL
The French Vodka brand will extend the energy of the US Open® beyond the court with the Last Serve Bar, offering fans one last GREY GOOSE Honey Deuce® signature cocktail of the US Open before heading home on the train after a daytime or evening match—open August 27–29 in Vanderbilt Hall. The GREY GOOSE Honey Deuce® cocktail remains a winning serve at this year's US Open, after generating over $12.8 million in sales with more than 556,000 cocktails sold in 2024 by the USTA. HAMILTON, Bermuda, Aug. 20, 2025 /PRNewswire/ -- GREY GOOSE® vodka is proud to announce its return to the US Open for the 19th year to serve the GREY GOOSE Honey Deuce® US Open signature cocktail. The French vodka brand once again invites fans to toast world-class tennis with the season's hottest accessory, this year going beyond the tournament grounds with a new, limited-time bar pop-up at Grand Central Terminal and renewed partnership with American tennis player Frances Tiafoe. For the first time, GREY GOOSE will give fans rushing to and from the US Open another moment to savor the infectious energy of the tournament with the Last Serve Bar: a chance to enjoy a GREY GOOSE Honey Deuce® US Open signature cocktail when heading back from watching a daytime or evening match at Arthur Ashe Stadium. The Last Serve Bar will be popping up on the east side of the station's Vanderbilt Hall from Wednesday, August 27 through Friday, August 29. For many tournament attendees, Grand Central Terminal is an integral part of the US Open experience. More than 60% of fans use mass transit to and from the USTA Billie Jean King National Tennis Center via the 7-subway line and Long Island Railroad (according to the MTA), and many thousands pass through the historic train station, creating a central hub for the excitement the tournament brings to New York City. Open from 5-8 pm and 10 pm-1 am each day, the Last Serve Bar will serve complimentary, on-trend "tiny 'tini" sample-sized GREY GOOSE Honey Deuce® and Espresso Martini cocktails for hustling commuters and late-night crowds looking to pause and make time wait. The bar will be unveiled with a spectacle of equally "grand" proportions: follow @ to stay tuned. GREY GOOSE has also teamed up with tennis star Frances Tiafoe for the second year. As a player that embodies cheerful style on and off the court, Tiafoe and GREY GOOSE will inspire fans to savor more moments of pleasure at the US Open, whether that's cheers-ing with a GREY GOOSE Honey Deuce® cocktail, enjoying a "last call" night cap at the brand's "Last Serve Bar" on the way home from the US Open, or sporting a joyful "tenniscore" fit. "The feeling at the US Open is electric—the crowds, the passion, the style. It's an energy unlike any other Grand Slams tournament and one that could only come from New York City, and I'm excited to keep it going with GREY GOOSE again this year," said Frances Tiafoe. "The GREY GOOSE Honey Deuce® cocktail has become a symbol of that joyful spirit. It's part of the culture, the look, and the celebration of the tournament." Since its debut 18 years ago, the GREY GOOSE Honey Deuce® signature cocktail of the US Open has evolved from a stadium concession to a cultural phenomenon: the exclusive signature cocktail of the US Open can be found on menus at top bars, in the hands of A-list celebrities, on the back of t-shirts and in airport lounges and even thousands of feet above Arthur Ashe Stadium on flights traveling worldwide. Not only is it the "season's hottest accessory," but it is also considered the "economic star of the tournament" with more than 556,000 sold at the 2024 tournament by the USTA— a 23.5% increase over year prior — resulting in a record-setting $12.8 million in sales. "The US Open is a premier sporting event that is truly unlike any other. There's an infectious joyful spirit that inspires people to dress up in their finest fits, enjoy a GREY GOOSE Honey Deuce® cocktail with friends and cheer on the best players from around the world," said Aleco Azqueta, Global Vice President of Marketing for GREY GOOSE vodka. "With our new Last Serve Bar at Grand Central Terminal, we are inviting fans to take a moment from their busy days to make time wait and savor the spirit of the tournament even after the last point is won." The GREY GOOSE Honey Deuce® is crafted with GREY GOOSE vodka, fresh lemonade, raspberry liqueur, and topped with tennis-inspired honeydew melon balls. This year, GREY GOOSE will have branded cocktail bars serving the pink-hued drink in four locations at the USTA Billie Jean King National Tennis Center: the Food Village, Grandstand, Louis Armstrong Stadium's concourse, and the promenade level of Arthur Ashe Stadium. For those tuning into the US Open tournament from home, GREY GOOSE will offer the Honey Deuce® Express service in New York, Chicago and, for the first time, Miami, delivering canned versions of the cocktail right to fans' front doors for the duration of the tournament via Uber Eats and Cocktail Courier. For more information, including a recipe to make GREY GOOSE Honey Deuce cocktails at home, please visit About GREY GOOSE vodkaMade without compromise, GREY GOOSE® is made with the highest-quality ingredients and has a 100% traceable production process, from crop to cork. Every aspect of the creation of GREY GOOSE® is focused on crafting vodka of unmatched quality. Each bottle of GREY GOOSE is distilled and bottled in France, with a recipe and process that remains unchanged since inception, using just two ingredients – single-origin Picardie wheat and spring water from our natural limestone well in Gensac-la-Pallue. A one-distillation process brings out the true essence of these ingredients. The GREY GOOSE portfolio is comprised of GREY GOOSE® vodka, GREY GOOSE® Altius, GREY GOOSE® La Poire, GREY GOOSE® L'Orange, and GREY GOOSE® Le Citron Flavored vodkas. SIP RESPONSIBLY. The GREY GOOSE vodka brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Press ContactsNike Communications - greygoose@ Wharton - cmwharton@ Didia - atdidia01@ View original content to download multimedia: SOURCE GREY GOOSE
Time Business News
6 hours ago
- Time Business News
Exploring Regulations Related to GBL Kaufen Across Europe
When it comes to chemical substances used across industries, one compound that often makes headlines is gamma-butyrolactone, more commonly known as GBL. Its versatility as a solvent and cleaner is widely recognized, yet the compound also carries strict legal scrutiny because of its potential misuse. For anyone curious about the rules surrounding gbl Kaufen (buying GBL) in Europe, understanding the patchwork of regulations can feel overwhelming. Different countries take different stances, and navigating these legal frameworks requires awareness and care. This blog takes a closer look at how GBL is regulated across Europe, what buyers should know, and why staying informed matters. GBL is a chemical solvent found in industrial cleaners, paint removers, and certain degreasers. In legitimate contexts, it plays an important role in manufacturing and cleaning industries. However, because GBL can convert into gamma-hydroxybutyrate (GHB) in the body, authorities view it as a substance with high potential for misuse. That dual-use nature both industrially valuable and potentially harmful—makes regulation complicated. Many European countries have implemented specific restrictions to control how gbl Kaufen takes place, ensuring buyers are legitimate businesses or individuals with valid purposes. The European Union doesn't have a single law that applies uniformly to all member states for GBL. Instead, it issues guidelines that countries can interpret and enforce individually. At the EU level, GBL is listed as a 'drug precursor,' meaning it can be controlled and monitored due to its potential use in producing banned substances. This classification does not automatically make gbl Kaufen illegal, but it does require that sales and purchases be tracked, with authorities paying close attention to unusual or suspicious activities. In Germany, GBL is tightly controlled. The government considers its potential misuse serious enough to impose stringent restrictions on how it can be sold and purchased. To legally buy GBL in Germany, companies usually need licenses and must demonstrate a clear industrial purpose for the chemical. Private buyers face significant barriers, and unauthorized purchases could lead to legal consequences. For Germans, gbl Kaufen is not as straightforward as clicking 'add to cart.' Instead, it requires proof of legitimacy, registration with authorities, and often, compliance checks. France also classifies GBL as a regulated substance. French authorities treat it as a chemical under strict monitoring, and buyers must prove industrial or laboratory usage. Over the years, France has taken strong action against unauthorized sales, including online vendors who attempt to bypass controls. This makes gbl Kaufen within France a heavily monitored process. While the UK is no longer part of the European Union, its stance on GBL is worth noting, especially for businesses trading across borders. In the UK, GBL is classified as a Class C controlled substance under the Misuse of Drugs Act when intended for human consumption. This means industrial and commercial uses are still permitted, but sellers and buyers must keep detailed records. Anyone attempting gbl Kaufen for personal use faces serious legal risks. The Netherlands has built its reputation on pragmatic drug policies, but when it comes to GBL, the rules are clear. Dutch authorities regulate sales to prevent misuse while still allowing industrial businesses to access the chemical. Vendors are required to verify the legitimacy of buyers. If someone attempts gbl Kaufen without proper documentation, the transaction will not proceed. This balanced approach aims to safeguard public health without unnecessarily harming legitimate industry operations. Across Europe, policies vary significantly: Spain : Authorities keep a close eye on GBL but generally allow industrial purchases with proper documentation. : Authorities keep a close eye on GBL but generally allow industrial purchases with proper documentation. Italy : Regulations exist but enforcement focuses on preventing diversion into unauthorized uses. : Regulations exist but enforcement focuses on preventing diversion into unauthorized uses. Nordic countries: Typically adopt very strict approaches, aligning closely with Germany's rules. In every case, gbl Kaufen requires navigating country-specific laws. Even if the EU provides general guidelines, enforcement rests on national governments. One of the biggest challenges regulators face is online sales. With e-commerce, buyers and sellers can connect across borders easily. However, customs authorities in Europe actively monitor shipments suspected of containing controlled chemicals. For instance, if someone tries to order GBL from a less-regulated country into Germany or France, the package could be seized, and legal consequences could follow. This means that online gbl Kaufen is not only risky but often legally problematic, especially without the proper licenses. At first glance, it may seem confusing why one country allows easier access to GBL while another imposes near-total restrictions. The reason lies in how each government assesses risk. Countries with a history of substance misuse tend to implement stricter laws. Nations with strong industrial reliance on GBL may focus on monitoring rather than outright bans. Legal traditions also shape enforcement some prefer heavy penalties, while others emphasize oversight and reporting. This patchwork creates a complex landscape for anyone interested in gbl Kaufen across Europe. Attempting to bypass regulations carries significant risks. Beyond the possibility of confiscated shipments, individuals or businesses could face: Heavy fines Criminal charges Blacklisting from suppliers Reputational damage Because of these risks, both companies and individuals should carefully research the legal status of gbl Kaufen in their specific country before making any purchase. If your industry requires GBL, here are some practical tips to stay compliant: Verify your supplier : Always check whether they are authorized to sell GBL. : Always check whether they are authorized to sell GBL. Keep documentation : Maintain purchase records, licenses, and proof of legitimate use. : Maintain purchase records, licenses, and proof of legitimate use. Stay updated : Laws can change, so follow national and EU-level updates. : Laws can change, so follow national and EU-level updates. Consult legal experts: Especially if your business operates across borders. Following these steps ensures that gbl Kaufen remains a safe and lawful process. Looking ahead, it's possible that the European Union will push for more harmonized regulations on substances like GBL. This could mean stricter monitoring across all member states or the development of a unified licensing system. For now, the fragmented system continues, and buyers must remain vigilant. Anyone involved in gbl Kaufen should prepare for potential regulatory tightening in the future. The story of GBL in Europe is one of balance: balancing legitimate industrial needs against the risks of misuse. Regulations vary from country to country, making it essential to understand local laws before making any purchase. Whether you're a business needing solvents for cleaning or manufacturing, or an individual researching chemical regulations, the key takeaway is clear: gbl Kaufen is not a one-size-fits-all process across Europe. Laws differ, enforcement varies, and compliance is critical. By staying informed and cautious, buyers can ensure they remain on the right side of the law while still accessing the chemical for legitimate purposes. TIME BUSINESS NEWS
